Demographic Information for Patients With History of Cosmetic Breast Surgery Compared With No History of Previous Cosmetic Breast Surgery
| Characteristic . | History of cosmetic breast surgery (%) . | P . | History of implant augmentation or augmentation mastopexy (%) . | P . | History of breast reduction . | P . | No history of cosmetic breast surgery . |
|---|---|---|---|---|---|---|---|
| Mean age, years (SD) | 52 (±10.2) | .213 | 52 (±9.8) | .304 | 53 (±11.0) | .485 | 53 (±11.0) |
| Mean BMI, kg/m2 (SD) | 24.8 (±4.3) | <.001 | 24.3 (±4.1) | <.001 | 27.0 (±4.5) | .352 | 27.6 (±6.0) |
| Race | |||||||
| Asian | 2 (1.6) | 2 (1.9) | 0 (0.0) | 67 (5.1) | |||
| Black | 4 (3.2) | .003 | 2 (1.9) | .004 | 1 (5.9) | .367 | 160 (12.2) |
| Hispanic | 9 (7.3) | 8 (7.8) | 0 (0.0) | 127 (9.7) | |||
| Other | 8 (6.5) | 6 (5.9) | 2 (11.8) | 95 (7.3) | |||
| White | 101 (81.5) | 84 (82.4) | 14 (82.4) | 847 (64.8) | |||
| Hypertension | 25 (20.2) | .043 | 22 (21.6) | .123 | 3 (17.6) | .316 | 371 (28.4) |
| Diabetes | 6 (4.8) | .368 | 3 (2.9) | .117 | 3 (17.6) | .089 | 90 (6.9) |
| Autoimmune | 10 (8.1) | .649 | 8 (7.8) | .739 | 2 (11.8) | .442 | 88 (6.7) |
| History of DVT or PE | 7 (5.6) | .330 | 5 (4.9) | .597 | 2 (11.8) | .096 | 47 (3.6) |
| Smoking status | |||||||
| Never | 93 (75.0) | 76 (74.5) | 12 (70.6) | 1010 (77.9) | |||
| Current | 3 (2.4) | .790 | 3 (2.9) | .711 | 0 (0.0) | .558 | 27 (2.1) |
| Former | 28 (22.6) | 23 (22.5) | 5 (29.4) | 259 (20.0) | |||
| Neoadjuvant chemotherapy | 24 (19.4) | .058 | 18 (17.6) | .036 | 4 (23.5) | .742 | 351 (26.9) |
| Neoadjuvant hormonal therapy | 4 (3.2) | .687 | 3 (2.9) | .872 | 1 (5.9) | .281 | 35 (2.7) |
| Adjuvant chemotherapy | 23 (18.5) | .142 | 18 (17.6) | .122 | 4 (23.5) | .982 | 324 (24.8) |
| Adjuvant hormonal therapy | 56 (45.2) | .049 | 51 (50.0) | .010 | 4 (23.5) | .669 | 500 (38.3) |
| Radiation | 38 (30.6) | .985 | 31 (30.4) | .974 | 6 (35.3) | .647 | 396 (30.3) |
| Characteristic . | History of cosmetic breast surgery (%) . | P . | History of implant augmentation or augmentation mastopexy (%) . | P . | History of breast reduction . | P . | No history of cosmetic breast surgery . |
|---|---|---|---|---|---|---|---|
| Mean age, years (SD) | 52 (±10.2) | .213 | 52 (±9.8) | .304 | 53 (±11.0) | .485 | 53 (±11.0) |
| Mean BMI, kg/m2 (SD) | 24.8 (±4.3) | <.001 | 24.3 (±4.1) | <.001 | 27.0 (±4.5) | .352 | 27.6 (±6.0) |
| Race | |||||||
| Asian | 2 (1.6) | 2 (1.9) | 0 (0.0) | 67 (5.1) | |||
| Black | 4 (3.2) | .003 | 2 (1.9) | .004 | 1 (5.9) | .367 | 160 (12.2) |
| Hispanic | 9 (7.3) | 8 (7.8) | 0 (0.0) | 127 (9.7) | |||
| Other | 8 (6.5) | 6 (5.9) | 2 (11.8) | 95 (7.3) | |||
| White | 101 (81.5) | 84 (82.4) | 14 (82.4) | 847 (64.8) | |||
| Hypertension | 25 (20.2) | .043 | 22 (21.6) | .123 | 3 (17.6) | .316 | 371 (28.4) |
| Diabetes | 6 (4.8) | .368 | 3 (2.9) | .117 | 3 (17.6) | .089 | 90 (6.9) |
| Autoimmune | 10 (8.1) | .649 | 8 (7.8) | .739 | 2 (11.8) | .442 | 88 (6.7) |
| History of DVT or PE | 7 (5.6) | .330 | 5 (4.9) | .597 | 2 (11.8) | .096 | 47 (3.6) |
| Smoking status | |||||||
| Never | 93 (75.0) | 76 (74.5) | 12 (70.6) | 1010 (77.9) | |||
| Current | 3 (2.4) | .790 | 3 (2.9) | .711 | 0 (0.0) | .558 | 27 (2.1) |
| Former | 28 (22.6) | 23 (22.5) | 5 (29.4) | 259 (20.0) | |||
| Neoadjuvant chemotherapy | 24 (19.4) | .058 | 18 (17.6) | .036 | 4 (23.5) | .742 | 351 (26.9) |
| Neoadjuvant hormonal therapy | 4 (3.2) | .687 | 3 (2.9) | .872 | 1 (5.9) | .281 | 35 (2.7) |
| Adjuvant chemotherapy | 23 (18.5) | .142 | 18 (17.6) | .122 | 4 (23.5) | .982 | 324 (24.8) |
| Adjuvant hormonal therapy | 56 (45.2) | .049 | 51 (50.0) | .010 | 4 (23.5) | .669 | 500 (38.3) |
| Radiation | 38 (30.6) | .985 | 31 (30.4) | .974 | 6 (35.3) | .647 | 396 (30.3) |
BMI, body mass index; DVT, deep vein thrombosis; PE, pulmonary embolism; SD, standard deviation.
Demographic Information for Patients With History of Cosmetic Breast Surgery Compared With No History of Previous Cosmetic Breast Surgery
| Characteristic . | History of cosmetic breast surgery (%) . | P . | History of implant augmentation or augmentation mastopexy (%) . | P . | History of breast reduction . | P . | No history of cosmetic breast surgery . |
|---|---|---|---|---|---|---|---|
| Mean age, years (SD) | 52 (±10.2) | .213 | 52 (±9.8) | .304 | 53 (±11.0) | .485 | 53 (±11.0) |
| Mean BMI, kg/m2 (SD) | 24.8 (±4.3) | <.001 | 24.3 (±4.1) | <.001 | 27.0 (±4.5) | .352 | 27.6 (±6.0) |
| Race | |||||||
| Asian | 2 (1.6) | 2 (1.9) | 0 (0.0) | 67 (5.1) | |||
| Black | 4 (3.2) | .003 | 2 (1.9) | .004 | 1 (5.9) | .367 | 160 (12.2) |
| Hispanic | 9 (7.3) | 8 (7.8) | 0 (0.0) | 127 (9.7) | |||
| Other | 8 (6.5) | 6 (5.9) | 2 (11.8) | 95 (7.3) | |||
| White | 101 (81.5) | 84 (82.4) | 14 (82.4) | 847 (64.8) | |||
| Hypertension | 25 (20.2) | .043 | 22 (21.6) | .123 | 3 (17.6) | .316 | 371 (28.4) |
| Diabetes | 6 (4.8) | .368 | 3 (2.9) | .117 | 3 (17.6) | .089 | 90 (6.9) |
| Autoimmune | 10 (8.1) | .649 | 8 (7.8) | .739 | 2 (11.8) | .442 | 88 (6.7) |
| History of DVT or PE | 7 (5.6) | .330 | 5 (4.9) | .597 | 2 (11.8) | .096 | 47 (3.6) |
| Smoking status | |||||||
| Never | 93 (75.0) | 76 (74.5) | 12 (70.6) | 1010 (77.9) | |||
| Current | 3 (2.4) | .790 | 3 (2.9) | .711 | 0 (0.0) | .558 | 27 (2.1) |
| Former | 28 (22.6) | 23 (22.5) | 5 (29.4) | 259 (20.0) | |||
| Neoadjuvant chemotherapy | 24 (19.4) | .058 | 18 (17.6) | .036 | 4 (23.5) | .742 | 351 (26.9) |
| Neoadjuvant hormonal therapy | 4 (3.2) | .687 | 3 (2.9) | .872 | 1 (5.9) | .281 | 35 (2.7) |
| Adjuvant chemotherapy | 23 (18.5) | .142 | 18 (17.6) | .122 | 4 (23.5) | .982 | 324 (24.8) |
| Adjuvant hormonal therapy | 56 (45.2) | .049 | 51 (50.0) | .010 | 4 (23.5) | .669 | 500 (38.3) |
| Radiation | 38 (30.6) | .985 | 31 (30.4) | .974 | 6 (35.3) | .647 | 396 (30.3) |
| Characteristic . | History of cosmetic breast surgery (%) . | P . | History of implant augmentation or augmentation mastopexy (%) . | P . | History of breast reduction . | P . | No history of cosmetic breast surgery . |
|---|---|---|---|---|---|---|---|
| Mean age, years (SD) | 52 (±10.2) | .213 | 52 (±9.8) | .304 | 53 (±11.0) | .485 | 53 (±11.0) |
| Mean BMI, kg/m2 (SD) | 24.8 (±4.3) | <.001 | 24.3 (±4.1) | <.001 | 27.0 (±4.5) | .352 | 27.6 (±6.0) |
| Race | |||||||
| Asian | 2 (1.6) | 2 (1.9) | 0 (0.0) | 67 (5.1) | |||
| Black | 4 (3.2) | .003 | 2 (1.9) | .004 | 1 (5.9) | .367 | 160 (12.2) |
| Hispanic | 9 (7.3) | 8 (7.8) | 0 (0.0) | 127 (9.7) | |||
| Other | 8 (6.5) | 6 (5.9) | 2 (11.8) | 95 (7.3) | |||
| White | 101 (81.5) | 84 (82.4) | 14 (82.4) | 847 (64.8) | |||
| Hypertension | 25 (20.2) | .043 | 22 (21.6) | .123 | 3 (17.6) | .316 | 371 (28.4) |
| Diabetes | 6 (4.8) | .368 | 3 (2.9) | .117 | 3 (17.6) | .089 | 90 (6.9) |
| Autoimmune | 10 (8.1) | .649 | 8 (7.8) | .739 | 2 (11.8) | .442 | 88 (6.7) |
| History of DVT or PE | 7 (5.6) | .330 | 5 (4.9) | .597 | 2 (11.8) | .096 | 47 (3.6) |
| Smoking status | |||||||
| Never | 93 (75.0) | 76 (74.5) | 12 (70.6) | 1010 (77.9) | |||
| Current | 3 (2.4) | .790 | 3 (2.9) | .711 | 0 (0.0) | .558 | 27 (2.1) |
| Former | 28 (22.6) | 23 (22.5) | 5 (29.4) | 259 (20.0) | |||
| Neoadjuvant chemotherapy | 24 (19.4) | .058 | 18 (17.6) | .036 | 4 (23.5) | .742 | 351 (26.9) |
| Neoadjuvant hormonal therapy | 4 (3.2) | .687 | 3 (2.9) | .872 | 1 (5.9) | .281 | 35 (2.7) |
| Adjuvant chemotherapy | 23 (18.5) | .142 | 18 (17.6) | .122 | 4 (23.5) | .982 | 324 (24.8) |
| Adjuvant hormonal therapy | 56 (45.2) | .049 | 51 (50.0) | .010 | 4 (23.5) | .669 | 500 (38.3) |
| Radiation | 38 (30.6) | .985 | 31 (30.4) | .974 | 6 (35.3) | .647 | 396 (30.3) |
BMI, body mass index; DVT, deep vein thrombosis; PE, pulmonary embolism; SD, standard deviation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
